Longitudinal MRI in multiple sclerosis

We followed 18 multiple sclerosis patients clinically and with repeated brain MRIs with and without gadolinium for over 1 year. Clinical evaluations included scoring on the Kurtzke Expanded Disability Status Scale (EDSS) and the Ambulation Index (AI) scale. There was a significant correlation between the change in EDSS or AI and the change in number of lesions on MRI and between cumulative number of lesions on MRI and cumulative change in EDSS or AI. Our findings support the validity of MRI as a measure of clinical activity and potentially as an objective quantitative outcome measure for assessing response to therapy.

[1]  J. Stevens,et al.  Multiple sclerosis: MRI and clinical correlation. , 1986, AJR. American journal of roentgenology.

[2]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[3]  B E Kendall,et al.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. , 1988, Brain : a journal of neurology.

[4]  H I Goldberg,et al.  Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. , 1988, Radiology.

[5]  G. Johnson,et al.  Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[6]  D. Li,et al.  Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients , 1989, Annals of neurology.

[7]  D. Li,et al.  Chronic progressive multiple sclerosis: Serial magnetic resonance brain imaging over six months , 1989, Annals of neurology.

[8]  A. Thompson,et al.  Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. , 1990, BMJ.

[9]  K. Syndulko,et al.  Quantitative multiple sclerosis plaque assessment with magnetic resonance imaging. Its correlation with clinical parameters, evoked potentials, and intra-blood-brain barrier IgG synthesis. , 1990, Archives of neurology.

[10]  Society of magnetic resonance in medicine , 1990 .

[11]  H Okazaki,et al.  Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. , 1991, Radiology.

[12]  A. Thompson,et al.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[13]  R. Murray,et al.  The effect of high‐dose steroids on MRI gadolinium enhancement in acute demyelinating lesions , 1991, Neurology.

[14]  S. Medendorp,et al.  Magnetic resonance imaging lesion enlargement in multiple sclerosis. Disease-related activity, chance occurrence, or measurement artifact? , 1992, Archives of neurology.

[15]  Roland Martin,et al.  Using gadolinium‐enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis , 1992, Annals of neurology.

[16]  H. McFarland,et al.  Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine–enhancing magnetic resonance imaging lesions , 1993, Annals of neurology.

[17]  W. I. McDonald,et al.  Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis , 1994, Neurology.